Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30182558 | 1.00 | HDAC4 (0.59) | HDAC4CA12CA1CA2CA7 | |
| SCHEMBL7826321 | 0.88 | HDAC4 (0.58) | HDAC4CA12CA1CA2CA7 | |
| SCHEMBL10044898 | 0.88 | HDAC4 (0.58) | HDAC4CA12CA1CA2CA7 | |
| SCHEMBL11983226 | 0.85 | EGFR (0.56) | HDAC4MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6996658 | 0.83 | ALDH1A1 (0.64) | HDAC4CA12CA1CA2CA7 | |
| SCHEMBL6994317 | 0.83 | HDAC4 (0.77) | HDAC4MAP3K5MEN1KMT2APOLB | |
| SCHEMBL2383493 | 0.83 | HIF1A (0.63) | HIF1A | |
| SCHEMBL15419154 | 0.82 | HDAC4 (0.53) | HDAC4MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL2385753 | 0.82 | HDAC4 (0.51) | HDAC4MAP3K5MEN1KMT2APOLB | |
| SCHEMBL2385748 | 0.82 | HDAC4 (0.51) | HDAC4MAP3K5MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277693-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2024-08-22 | — | — | US | claimed |
| EP-4363404-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | Active Biotech AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-117500790-A | Pharmaceutical product containing taquinimod and method for evaluating purity of said product | 活跃生物技术有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2023275248-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2023-01-05 | — | — | WO | claimed |
| US-9216956-B2 | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | ACTIVE BIOTECH AB (SE) | 2015-12-22 | — | — | US | claimed |
| US-20140112946-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | ACTIVE BIOTECH AB (SE) | 2014-04-24 | — | — | US | claimed |
| EP-2537517-A1 | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | Active Biotech AB (SE) | 2012-12-26 | — | — | EP | claimed |
| US-20240277693-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2024-08-22 | — | — | US | disclosed |
| EP-4363404-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | Active Biotech AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| CN-117500790-A | Pharmaceutical product containing taquinimod and method for evaluating purity of said product | 活跃生物技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023275248-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275248-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | ACTIVE BIOTECH AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| CN-108358842-A | His quinoline not crystal form of moral and preparation method thereof, its pharmaceutical composition and purposes | 杭州普晒医药科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-1309641-A | Quinoline derivs. | ACTIVE BIOTECH AB (SE) | 2001-08-22 | — | — | CN | disclosed |
| EP-1095021-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | disclosed |
| WO-2000003991-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140112946-A1 | DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | H1-5, MALT1, H1-4 | HDAC4 249/4885CA12 2761/4885CA1 2733/4885 |
| US-20240277693-A1 | A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT | TPMT, TLR7, MYD88 | HDAC4 1044/4885CA12 4126/4885CA1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.